Search Results
Found 2 results
510(k) Data Aggregation
(73 days)
EPIQ Series Diagnostic Ultrasound System: The intended use of EPIQ Ultrasound Diagnostic System is diagnostic ultrasound imaging and fluid flow analysis of the human body, with the following indications for use: Abdominal, Cardiac Adult, Cardiac other (Fetal), Cardiac Pediatric, Cerebral Vascular, Cephalic (Adult), Cephalic (Neonatal), Fetal/Obstetric, Gynecological, Intraoperative (Vascular), Intraoperative (Cardiac), intra-luminal, intra-cardiac echo, Musculoskeletal (Conventional), Musculoskeletal (Superficial), Ophthalmic, Other: Urology, Pediatric, Peripheral Vessel, Small Organ (Breast, Thyroid, Testicle), Transesophageal (Cardiac), Transrectal, Transvaginal, Lung.
Modes of operation include: B Mode, M Mode, PW Doppler, CW Doppler, Color Doppler, Color M Mode, Power Doppler, and Harmonic Imaging.
The clinical environments where EPIQ Series Diagnostic ultrasound Systems can be used include clinics, hospitals, and clinical point-of-care for diagnosis of patients.
When integrated with Philips EchoNavigator, the systems can assist the interventionalist and surgeon with image guidance during treatment of cardiovascular disease in which the procedure uses both live X-ray and live echo guidance.
The systems are intended to be installed, used, and operated only in accordance with the safety procedures and operating instructions given in the product user information. Systems are to be operated only by appropriately trained healthcare professionals for the purposes for which they were designed. However, nothing stated in the user information reduces your responsibility for sound clinical judgement and best clinical procedure.
Affiniti Series Diagnostic Ultrasound Systems: The intended use of Affiniti Series Diagnostic Ultrasound Systems is diagnostic ultrasound imaging and fluid flow analysis of the human body, with the following indications for use: Abdominal, Cardiac Adult, Cardiac Other (Fetal), Cardiac Pediatric, Cerebral Vascular, Cephalic (Adult), Cephalic (Neonatal), Fetal/Obstetric, Gynecological, Intraoperative (Vascular), Intraoperative (Cardiac), Musculoskeletal (Conventional), Musculoskeletal (Superficial), Other: Urology, Pediatric, Peripheral Vessel, Small Organ (Breast, Thyroid, Testicle), Transesophageal (Cardiac), Transrectal, Transvaginal, Lung.
Modes of operation include: B Mode, M Mode, PW Doppler, CW Doppler, Color Doppler, Color M Mode, Power Doppler, and Harmonic Imaging.
The clinical environments where the Affiniti diagnostic ultrasound systems can be used include clinics, hospitals, and clinical point-of-care for diagnosis of patients. The systems are intended to be installed, used, and operated only in accordance with the safety procedures and operating instructions given in the product user information. Systems are to be operated only by appropriately trained healthcare professionals for the purposes for which they were designed. However, nothing stated in the user information reduces your responsibility for sound clinical judgement and best clinical procedure.
The purpose of this 510(k) Pre-market Notification is to introduce the SVS v2 Contrast software application with the EPIQ and Affiniti Series Diagnostic Ultrasound Systems as part of the VM13.0 program.
SVS v2 Contrast is an automated software feature that assists in the selection of images for analysis with the new Philips license options 2D Auto EF Advanced (Adv) developed by DiA Imaging Analysis (K243235), now part of Philips Ultrasound LLC, and existing Philips license options AutoStrain LV; or 2D Auto LV (both K240850) license application in Adult Echo Transthoracic (TTE) examinations.
As described in 510(k) K240850, this feature automatically classifies each acquired image by view and selects an appropriate set of images for Left ventricle (LV) analysis. The classification is based on a Deep Learning AI inference engine; the selection is a non-AI algorithm that considers the view classification and image depth to select the optimal set of images. The difference in SVS v2 Contrast from the predicate SVS v1 (K240850) is that the algorithm is revised to include the selection of optimal images for analysis when contrast is used in routine TTE exams.
Users can launch existing 2D Auto EF; 2D Auto EF Adv; AutoStrain LV; or 2D Auto LV with the set of images that have been automatically selected without the need to review the acquired images and manually select the views. Users may select 2D Auto EF Adv, to process the selected views by SVS v2 Contrast. SVS v2 Contrast prioritizes the contrast image pair; however, if an appropriate pair of contrast images is not found, then Auto EF Adv may select non-contrast images. The manual approach to select views is still available and the user can override automatically selected images from SVS v2 Contrast.
No hardware changes to the EPIQ or Affiniti Series Diagnostic Ultrasound Systems are required when using SVS v2 Contrast, and existing, cleared Philips TTE transducers.
The SVS v2 Contrast feature is supported by all EPIQ models running software version 13.0 or higher including EPIQ CVx/CVxi, EPIQ Elite Advanced, EPIQ Elite, EPIQ 7, EPIQ 5. The SVS v2 Contrast feature is supported by the Affiniti models running software version VM13.0 or higher, including Affiniti CVx, Affiniti 70, Affiniti 50, and Affiniti 30. The SVS v2 Contrast feature is associated with the cardiac adult indication.
Acceptance Criteria and Study Details for SVS v2 Contrast Software
This document outlines the acceptance criteria and details of the study conducted to demonstrate that the Philips Ultrasound systems (EPIQ and Affiniti Series Diagnostic Ultrasound System) with the SVS v2 Contrast software application meet the established performance benchmarks.
1. Table of Acceptance Criteria and Reported Device Performance
Criteria | Acceptance Criteria | Reported Device Performance (SVS Selected vs Manually Selected Ground Truth) |
---|---|---|
Primary Endpoint: Pearson's correlation coefficient (r) for Biplane EF (Automated Selection vs. Manual Selection) | Lower Confidence Bound for the Pearson's correlation coefficient (r) to be > 0.8. (Informed by published literature (Maret, E. B. (2008)) and previous regulatory submissions (K130779, K232500)). Note: The manual selection here refers to "manual contrast clip selection," which was automatically processed within the Contrast EF application, with the automated EF results serving as ground truth. | N = 46: r = 0.953 (95% CI: 0.917, 0.974), p-value 0.8, meeting the acceptance criteria. |
Agreement Assessment: Bland-Altman Analysis for Biplane EF (Automated Selection vs. Manual Selection) | Acceptable performance for automatic selection of appropriate clips by SVS software and subsequent output of Contrast Enhanced Biplane EF feature compared to the results of Contrast Enhanced Biplane EF from manually selected contrast clips. (No specific numerical thresholds provided for Bland-Altman, but indicated as demonstrating "acceptable performance" if the primary endpoint is met). | N = 46: Mean Difference ± SD = 0.71 ± 4.36 (95% CI for Mean Difference: -0.58, 2.01). Lower LoA = -7.83 (95% CI: -10.06, -5.60), Upper LoA = 9.26 (95% CI: 7.03, 11.49). Reported as demonstrating acceptable performance. |
Agreement Assessment: Pearson's correlation coefficient (r) for Biplane EF (Automated Selection vs. Manual Tracing Ground Truth) | No explicit independent acceptance criterion for this comparison; serves as an additional supporting analysis. | N = 46: r = 0.938 (95% CI: 0.890, 0.965), p-value |
Ask a specific question about this device
(28 days)
EPIQ: The intended use of Philips EPIQ series diagnostic ultrasound systems is diagnostic ultrasound imaging and fluid flow analysis of the human body, with the following indications for use: Abdominal, Cardiac Adult, Cardiac other (Fetal), Cardiac Pediatric, Cerebral Vascular, Cephalic (Adult), Cephalic (Neonatal), Fetal/Obstetric, Gynecological, Intraoperative (Vascular), Intraoperative (Cardiac), Intra-luminal, Intra-cardiac Echo, Musculoskeletal (Conventional), Musculoskeletal (Superficial), Ophthalmic, Other: Urology, Pediatric, Peripheral Vessel, Small Organ (Breast, Thyroid, Testicle), Transesophageal (Cardiac), Transrectal, Transvaginal, Lung.
Affiniti: The intended use of the Affiniti Series Diagnostic Ultrasound Systems is diagnostic ultrasound imaging and fluid flow analysis of the human body with the following Indications for Use: Abdominal, Cardiac Adult, Cardiac other (Fetal), Cardiac Pediatric, Cerebral Vascular, Cephalic (Adult), Cephalic (Neonatal), Fetal/Obstetric, Gynecological, Intraoperative (Vascular), Intraoperative (Cardiac), Musculoskeletal (Conventional), Musculoskeletal (Superficial), Other: Urology, Pediatric, Peripheral Vessel, Small Organ (Breast, Thyroid, Testicle), Transesophageal (Cardiac), Transrectal, Transvaginal, Lung.
The purpose of this Special 510(k) Pre-Market Notification is to modify the Segmental Wall Motion and introduce Auto EF with contrast software application onto the Philips EPIQ Series Diagnostic Ultrasound System and Affiniti Series Diagnostic Ultrasound Systems. SWM algorithm was previously cleared (K243862) and Auto EF contrast algorithm(K243235) was also previously cleared. The current software release version VM 13, replaces the previous version of the segmental wall motion algorithm included in version 11 of the software release with the current cleared version (K243862) without any modifications, and integrates Auto EF contrast algorithm(K243235) without any modifications into one software release.
The SWM v2 software automatically evaluates the segmental (regional) function of the left ventricle (LV) from adult TTE echo examinations. For input, the SWM algorithm uses 3 apical views (A4C, A2C and A3C) and performs border detection and tracking to identify each of the LV segments based on the three views. The SWM v2 software is a semi-automated quantitative imaging algorithm, as users are generally expected to review and concur with the initial and generated results. The users can also manually edit algorithm-generated segmental wall motion scores for individual segments based on their clinical expertise.
Auto EF with contrast is an AI based automated software feature that assists clinicians with assessing Left Ventricular Ejection Fraction (LVEF) from images acquired with contrast agent as part of an adult transthoracic echo (TTE) examination. The feature is located within the Philips Auto EF Adv application. Auto EF with contrast uses 2 apical views (Apical four chamber view (A4C), Apical two chamber (A2C)) and provides EF for each view and a biplane Simpsons EF.
No hardware changes to the EPIQ or Affiniti systems were made due to the SWM v2 and Auto EF with contrast, and existing, cleared Philips TTE transducers are used with these software applications.
This FDA 510(k) clearance (K251110) modifies the Segmental Wall Motion (SWM) algorithm and integrates an existing Auto EF with contrast software into Philips EPIQ and Affiniti Series Diagnostic Ultrasound Systems. The study details for each software component are primarily based on retrospective data analyses.
Here's a breakdown of the acceptance criteria and study information for each feature:
SWM v2 (Segmental Wall Motion v2)
Information Requested | Description |
---|---|
1. Acceptance Criteria and Reported Device Performance | Acceptance Criteria: Sensitivity and specificity of WMSI > 0.675 (Lower Bound of the Confidence Interval) based on a predefined prevalence of abnormal cases of 65%. The expected value of the correlation coefficient is 0.8, and the lower bound is 0.675, computed for Sensitivity, with a power of 80%, a one-sided alpha of 0.025, a prevalence of 65%, and a target sensitivity of 0.80. No acceptance criteria were defined specifically for Philips data, but the objective was to ensure similar trends in performance. |
Reported Performance: "The SWM v2 software applied to Philips data shows performance that aligns with previously reported assessment of the algorithm (K243862)." "The reported sensitivity and specificity of the SWM v2 software as compared to visual estimation of WMSI, indicate that the safety and effectiveness of the proposed subject software, SWM v2, is acceptable and aligns with the previously reported performance." (Specific numerical values for sensitivity and specificity for this clearance are not provided, only a statement of alignment with previous clearance K243862). | |
2. Sample Size & Data Provenance (Test Set) | Sample Size: Not explicitly stated for this particular evaluation, but the study was a retrospective data analysis. |
Data Provenance: Transthoracic (TTE) ultrasound clips obtained from subjects referred for clinical TTE exam. No country of origin is specified, but the data originates from "Philips data." The study was retrospective. | |
3. Number & Qualifications of Experts (Ground Truth) | Number of Experts: 3. |
Qualifications: "expert cardiologists." (No specific years of experience or subspecialty mentioned other than "cardiologist"). | |
4. Adjudication Method (Test Set) | Two approaches for sensitivity and specificity analyses were tested: |
- Comparison of the average WMSI from ground truthers to the SWM v2 software's WMSI.
- Majority agreement: A minimum of 2 out of 3 ground truthers were required to agree on WMSI = 1 (normal) or WMSI > 1 (abnormal) for the exam, which was then compared to the software's WMSI. |
| 5. Multi-Reader Multi-Case (MRMC) Study | No, an MRMC comparative effectiveness study was not explicitly described. The study compared the algorithm's performance to expert visual estimation as the ground truth. |
| 6. Standalone Performance | Yes, this was a standalone (algorithm only) performance evaluation against an expert-established ground truth. Although it is a "semi-automated quantitative imaging algorithm" where "users are generally expected to review and concur," the performance assessment described here focuses on the algorithm's output prior to user editing. |
| 7. Type of Ground Truth Used | Expert consensus/visual estimation by 3 expert cardiologists. |
| 8. Training Set Sample Size | Not provided in this document. This clearance refers to a previous clearance (K243862) for the SWM v2 algorithm. |
| 9. Training Set Ground Truth Establishment | Not provided in this document. This clearance refers to a previous clearance (K243862). |
Auto EF with Contrast
Information Requested | Description |
---|---|
1. Acceptance Criteria and Reported Device Performance | Acceptance Criteria: Lower Confidence Bound for the Pearson's correlation to be > 0.75. The expected value of the correlation coefficient is 0.85, and the lower bound is 0.75, computed with 80% power to detect a difference of -0.10 between the null hypothesis correlation of 0.75 and the alternative hypothesis correlation of 0.85 using a one-sided hypothesis test with a significance level of 0.025. |
Reported Performance: The acceptance criteria for the primary endpoint were met. The Pearson's correlation coefficient and associated confidence intervals are 0.952 (95%CI 0.919, 0.972). | |
2. Sample Size & Data Provenance (Test Set) | Sample Size: Not explicitly stated. |
Data Provenance: Transthoracic (TTE) contrast-enhanced clips obtained from subjects referred for clinical TTE exam. A sub-analysis was performed on data acquired with Philips systems. No country of origin is specified. The study was retrospective. | |
3. Number & Qualifications of Experts (Ground Truth) | Number of Experts: 3 sonographers for initial assessment and 1 cardiologist for final review. |
Qualifications: "qualified sonographers" and "Cardiologist specializing in echo." (No specific years of experience are provided). | |
4. Adjudication Method (Test Set) | Consensus with physician review: |
- Manual selection of clips by an experienced sonographer.
- Manual EF assessment using Simpson's method of disks by 3 qualified sonographers.
- "Shoulder to shoulder" consensus meetings among the 3 sonographers to review manual measurements, jointly select best traced images ("Best Trace"), and adjust traces if needed.
- A cardiologist specializing in echo subsequently reviewed the selected A4C and A2C clips with "Best Trace" and the resulting LV EF measurements, performing manual adjustments if needed. These final measurements were used as ground truth. |
| 5. Multi-Reader Multi-Case (MRMC) Study | No, an MRMC comparative effectiveness study was not explicitly described. This was a direct comparison of the algorithm's standalone performance against a consensus-derived ground truth. |
| 6. Standalone Performance | Yes, the study describes the "Contrast EF application to an EF output" in an automated fashion, and "The ground truth EF measurements were compared to the Contrast EF automated results for EF (biplane)." This indicates a standalone performance evaluation. |
| 7. Type of Ground Truth Used | Expert consensus (between 3 sonographers and 1 cardiologist) using manual EF assessment via Simpson's method of disks. |
| 8. Training Set Sample Size | Not provided. This clearance refers to a previous clearance (K243235) for the Contrast EF algorithm. |
| 9. Training Set Ground Truth Establishment | Not provided. This clearance refers to a previous clearance (K243235). |
Overall Context:
It's important to note that this 510(k) is a Special 510(k). This type of submission is usually for modifications to a currently cleared device where the changed device does not raise new questions of safety and effectiveness. Both SWM v2 and Auto EF with contrast were previously cleared as standalone applications (K243862 and K243235, respectively). This clearance focuses on integrating these previously cleared algorithms into the Philips EPIQ and Affiniti ultrasound systems and replacing an older SWM algorithm. Therefore, the performance studies described here are primarily to demonstrate that the algorithms maintain their previously established performance when integrated into the new platform, or to provide updated performance data for the newer version of the SWM algorithm.
Ask a specific question about this device
Page 1 of 1